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Abstract
The high-risk human papillomavirus (HPV) E6 proteins are consistently expressed in HPV-associated lesions and cancers.
HPV16 E6 sustains the activity of the mTORC1 and mTORC2 signaling cascades under conditions of growth factor
deprivation. Here we report that HPV16 E6 activated mTORC1 by enhanced signaling through receptor protein tyrosine
kinases, including epidermal growth factor receptor and insulin receptor and insulin-like growth factor receptors. This is
evidenced by sustained signaling through these receptors for several hours after growth factor withdrawal. HPV16 E6
increased the internalization of activated receptor species, and the signaling adaptor protein GRB2 was shown to be critical
for HPV16 E6 mediated enhanced EGFR internalization and mTORC1 activation. As a consequence of receptor protein kinase
mediated mTORC1 activation, HPV16 E6 expression increased cellular migration of primary human epithelial cells. This study
identifies a previously unappreciated mechanism by which HPV E6 proteins perturb host-signaling pathways presumably to
sustain protein synthesis during the viral life cycle that may also contribute to cellular transforming activities of high-risk
HPV E6 proteins.
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Introduction
Human papillomaviruses (HPVs) are small viruses with double
stranded DNA genomes that infect squamous epithelial tissue.
Approximately 200 HPV types have been identified and
categorized based on the type of host epithelial tissue they infect.
A subset of HPVs infects the mucosal epithelium, and high-risk
mucosal HPVs cause lesions that can undergo malignant
progression. High-risk HPVs are the causative agents for nearly
100% of cervical cancers.
A frequent hallmark of HPV-associated carcinogenesis is the
integration of the HPV genome into a host chromosome. This
results in the dysregulated expression of the viral E6 and HPV E7
proteins. These two proteins together are sufficient to cause
cervical carcinoma in a transgenic mouse model and are necessary
for the maintenance of the transformed state of cervical cancer cell
lines (reviewed in reference [1]). High-risk HPV E6 proteins form
a complex with the E3 ubiquitin ligase UBE3A (E6AP) and the
p53 tumor suppressor, targeting p53 proteasomal degradation [2].
The E6/UBE3A complex can also target other cellular proteins
for degradation, including members of a diverse group of cellular
PDZ proteins that associate with high-risk HPV E6 proteins
through their carboxyl-terminal PDZ binding domains [3–10].
High-risk HPV E6 proteins also contribute to the immortalization
of the host cell through transcriptional activation of hTERT, the
catalytic component of the human telomerase enzyme [11].
HPVsinfectthe basal epithelial cells,which occupy a nutrient rich
environment.Thesecellsgenerallyundergoasymmetriccelldivision,
where one daughter cell remains a basal cell whereas the other
daughter cell is poised to undergo differentiation to form the
stratified squamous epithelium. Viral genome replication and
progeny synthesis is confined to terminally differentiated cells in
upper layers of the epithelium. Through inactivation of the p53 and
pRB tumor suppressors,theHPV E6and E7proteins keep suchcells
in a DNA synthesis competent state but it is unknown how
completion of the viral life cycle may occur ina cellular environment
thatpresumablyisrestrictedfornutrientsandenergysourcesthatare
required for DNA replication and protein synthesis. HPV16 E7
expression has been reported to cause a metabolic switch from
oxidative phosphorylation to anaerobic fermentation, a phenome-
non referred to as the ‘‘Warburg effect’’ [12]. Moreover, HPV16 E7
expressing cells exhibit evidence of autophagy even when grown in
rich growth media [13]. When deprived of serum, normal cells
undergo G1 growth arrest, but HPV16 E7 expressing cells continue
toproliferate and eventuallyexpirethroughcaspase independent cell
death [14]. This reflects a cellular tumor suppressive response to
HPV E7 expression that has been termed the trophic sentinel
response [15]. Co-expression of HPV16 E6 abrogates HPV16 E7
triggered trophic sentinel signaling. Presumably to overcome the E7
triggered trophic sentinel response, HPV16 E6 activates mTORC1
signaling and increases protein synthesis under normal growth
conditions and upon growth factor withdrawal [16–18].
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PDK1 and mTORC2 under conditions of nutrient deprivation
[16]. PDK1 is downstream of PI3K and is activated through
several membrane-associated signaling events including the
activation of ERBB, insulin receptor (INSR) and insulin-like
growth factor receptor (IGFR) receptor protein tyrosine kinases
(RPTKs). Following ligand binding, RPTKs dimerize, initiating
receptor autophosphorylation on multiple tyrosine residues within
the intracellular domains. Adaptor proteins are then recruited to
the tyrosine phosphorylated receptors via their SH2 domains and
activate downstream effector cascades. Activated EGFR associates
with multiple signaling adaptor proteins including growth factor
receptor-bound protein 2 (GRB2), Src homology 2 domain
containing (SHC), and phosphoinositide phospholipase Cc (PLCc)
[19–21]. Similarly, INSR and IGFR are autophosphorylated in a
conserved kinase activation loop followed by tyrosine phosphor-
ylation within the intracellular domain that triggers downstream
effector signaling [22,23]. ERBB and INSR/IGFR receptor
activation trigger common downstream signaling cascades includ-
ing AKT and mTORC1. ERBB and INSR/IGFR autophospho-
rylation induces receptor internalization through clathrin mediat-
ed endocytosis, an event that is associated with active signaling and
can either lead to receptor recycling to the cell surface or receptor
degradation [24,25].
Here we report that HPV16 E6 expressing primary human
foreskin keratinocytes (HFKs) show evidence of RPTK hyperac-
tivity when grown in normal growth medium and that RPTK
signaling is sustained over prolonged periods of time when the cells
are deprived of the corresponding growth factors. We show that
HPV16 E6 increases phosphorylation of INSR, IGFR, and EGFR
RPTKs. We also show that HPV16 E6 expression causes an
increase in the internalization of activated, phosphorylated
RPTKs. We discovered that small molecule RPTK inhibitors as
well as GRB2 depletion abrogates mTORC1 activity suggesting
that E6 mediated mTORC1 activation is caused by enhanced
RPTK activity. Moreover, we show that GRB2 depletion also
specifically impairs EGF internalization in HPV16 E6 expressing
cells. HPV16 E6 mediated RPTK activation causes an increase in
mTORC1-dependent cellular migration in the absence of growth
factors, which may be relevant to HPV associated carcinogenesis.
Results
Prolonged activity of receptor protein tyrosine kinase
signaling pathways after EGF deprivation in HPV16 E6
expressing HFKs
We previously reported that HPV16 E6 activates S6K and 4E-
BP1 through mTORC1 and that persistent AKT phosphorylation
under conditions of nutrient deprivation resulted from PDK1 and
mTORC2 activation [16]. To determine the mechanism of
activation, we first took a general approach and evaluated global
tyrosine phosphorylation under conditions of growth factor
deprivation (-EGF) and general nutrient deprivation (PBS).
Activation of RPTK signaling is initiated by the autophosphory-
lation of tyrosine residues on the intracellular domains of these
proteins. Hence, we evaluated global tyrosine phosphorylation in
donor matched populations of primary human foreskin keratino-
cytes (HFKs) expressing HPV16 E6 or transduced with control
vector by immunoblotting with a phosphotyrosine specific
antibody. Compared to control cells, tyrosine phosphorylation
was increased in HPV16 E6 expressing HFKs grown for 2 hours
in the absence of EGF in the growth medium (Figure 1A, left) or
under conditions of nutrient deprivation in PBS for 15 minutes
(Figure 1A, right).
Autophosphorylation of specific tyrosine residues in the
intracellular domain of EGFR causes recruitment of adaptor
proteins and activation of effector signaling pathways. We
therefore evaluated EGFR autophosphorylation at specific tyro-
sine residues. In EGF deprived HPV16 E6 expressing HFKs, we
observed prolonged EGFR autophosphorylation on Y992, Y1068,
and Y1173, which are associated with PLCc activation, GRB2
binding and MAPK/PI3K signaling, and SHC binding and
MAPK signaling, respectively (Figure 1B). To determine whether
HPV16 E6 may be activating multiple RPTKs, we also evaluated
the phosphorylation/activity status of insulin receptor-b (INSRb)
and insulin-like growth factor receptor-b (IGFRb) utilizing an
antibody that recognizes specific phosphorylated tyrosine resides
on both receptors: Y1135/36 on INSRb and Y1150/51 on
IGFRb. Similar to what we observed with EGFR, autophospho-
rylation of INSRb and/or IGFRb at these sites was sustained at
higher levels in PBS treated HPV16 E6 expressing HFKs than in
control HFKs (Figure 1C).
Thus activation of EGFR, and well as INSRb and/or IGFRb is
sustained at higher levels and over prolonged periods of time in
HPV16 E6 expressing HFKs after growth factor or nutrient
deprivation.
Activation of RPTK effector signaling in HPV16 E6
expressing HFKs
It has been reported that HPV16 E6 activates mTORC1
[16,17], and that E6 mediated mTORC1 activation causes an
increase in translation of capped mRNAs [16]. HPV16 E6 has also
been reported to activate FAK signaling, which is also linked to
RPTK activation [26,27]. Given that we detected prolonged
EGFR Y1068 and Y1173 phosphorylation, and INSRb/IGFRb
phosphorylation at Y1150/51 and Y1135/36, respectively, which
are associated with initiation of RAS/MAPK signaling, we
evaluated MAPK activity under conditions of EGF withdrawal.
We observed prolonged phosphorylation and activation of the
MAPK effectors ERK1/2 in HPV16 E6 expressing HFKs, and
the ERK substrate RSK was phosphorylated at higher levels in
HPV16 E6 expressing HFKs than in control cells (Figure 2A). In
Author Summary
High-risk human papillomavirus infections are associated
with nearly all cases of cervical cancer. HPVs infect basal
epithelial cells but virion production is restricted to the
outer, terminally differentiated layers of the infected
epithelia where supply of nutrients and growth factors
may be limited. High-risk HPV E6 proteins have been
shown to activate mTORC1 signaling and increase cap
dependent translation. Here we show that HPV16 E6
activates the mTORC1 and MAP kinase signaling pathways
through activating receptor protein tyrosine kinases
(RPTKs) and increases EGFR internalization, even after
growth factor withdrawal. The signaling adaptor protein
GRB2 is a critical mediator of HPV16 E6 mediated EGFR
internalization and mTORC1 activation. Lastly, we demon-
strate that HPV16 E6 mediated activation of RPTK and
mTORC1 signaling causes increased cellular migration
even after growth factor withdrawal. These results suggest
a previously unappreciated mechanism by which HPV E6
proteins may support the viral life cycle and that may
contribute to the transforming activities of high-risk HPV
E6 proteins. Hence, inhibition of RPTK signaling networks
may be evaluated as a therapeutic strategy for HPV-
associated lesions and cancers.
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dependent translation through RSK mediated phosphorylation of
the ribosomal protein S6 on serine residues 235 and 236 (S6
S235/36). To determine if MAPK signaling is required for HPV16
E6 to activate cap dependent translation, we utilized a bicistronic
luciferase reporter assay [28]. U2OS human osteosarcoma cells
were transiently transfected with the reporter construct and a
vector expressing HPV16 E6 or empty vector, and MAPK activity
was inhibited with the MEK inhibitor U0126. We found that cap
dependent translation in control as well as E6 expressing cells is
sensitive to MEK inhibition (Figure 2B, grey bars). We previously
reported that HPV16 E6 activates cap dependent translation at
least in part through mTORC1 [16]. To determine the relative
contributions of MAPK and mTORC1 activation, we co-treated
cells with Rapamycin and U0126 to simultaneously inhibit
mTORC1 and MAPK. Similar to control cells, co-treatment of
HPV16 E6 expressing cells with Rapamycin caused an additional
decrease in cap-dependent translation (Figure 2B, black bars;
P,0.05). Western blots demonstrate that U0126 treatment
effectively inhibits MEK signaling (Figure S1).
Reduced mTORC1 activity after EGFR or INSR/IGFR
inhibition in HPV16 E6 expressing HFKs
To determine whether RPTK activity is necessary for HPV16
E6 mediated mTORC1 activation, we treated HPV16 E6
expressing HFKs and control HFKs growing in normal culture
media (KSFM) with the EGFR inhibitor Gefitinib and analyzed
the phosphorylation status of the mTORC1 substrate S6 kinase
(S6K). As predicted, we observed a rapid reduction of EGFR
Y1068 autophosphorylation in control and HPV16 E6 expressing
HFKs (Figure 3A). EGFR inhibition with Gefitinib treatment also
partially inhibited S6K phosphorylation. Treatment with OSI-
906, a dual kinase inhibitor of INSRb and IGFRb, caused rapid
INSRb and IGFRb dephosphorylation in control and HPV16 E6
expressing HFKs (Figure 3B). At short time points after OSI-906
treatments, we reproducibly observed a spike of increased S6K
phosphorylation in both control and HPV16 E6 expressing cells.
This might represent compensatory S6K phosphorylation, per-
haps via EGFR/PI3K/AKT signaling, consistent with a study that
reported AKT activation upon MAPK inhibition [29].
These results suggest that EGFR and INSRb/IGFRb RPTKs
each contribute to mTORC1 activation in HPV16 E6 expressing
HFKs, under normal growth conditions.
Increased internalization of activated receptor species in
HPV16 E6 expressing HFKs
Since HPV16 E6 expressing cells exhibit prolonged RPTK and
AKT activation after growth factor withdrawal, we evaluated
internalization of activated EGFR, INSRb and IGFRb. HFKs
were starved in PBS, and cell surface proteins were conjugated to
biotin. The cells were then incubated in KSFM lacking EGF and
other supplements for 180 minutes in order to promote ligand
independent internalization. Cells were then treated with gluta-
thione and lysed to measure internalized receptors. As a control,
total cell surface receptors were measured by directly lysing cells
without stimulation or subsequent glutathione reduction. Affinity
purification with streptavidin conjugated beads was used to isolate
biotin conjugated proteins and active receptor species were
detected using phosphospecific antibodies. These experiments
revealed that HPV16 E6 expressing cells show increased
internalization of active, phosphorylated EGFR as well as INSRb
and/or IGFRb in the absence of growth factors (Figure 4A).
To independently validate that HPV16 E6 increases EGFR
internalization under different experimental conditions and by a
different approach, we stimulated EGF-starved HFKs with Alexa-
647 EGF and evaluated co-localization of EGF with the early
endosomal marker autoantigen 1 (EEA1) after 15 minutes by
fluorescence microscopy. Compared to matched vector transduced
HFKs, HPV16 E6 expressing HKFs had an increased number of
EGF positive early endosomes (Control=3.4060.54; HPV16
E6=5.6760.65 EGF/EEA1 positive vesicles, P=0.0017)
(Figure 4B and C).
Figure 1. ERBB2 phosphorylation is increased in HPV16 E6 expressing HFKs. (A) Western blot analysis of proteins with phosphorylated
tyrosine residues following EGF withdrawal (left) or PBS starvation (right) from HFK lysates stably expressing HPV16 E6 (E6) or the pLentiN6.3 control
vector (C). (B) and (C) Western blot analyses probing the phosphorylation status of EGFR (B) or INSRb/IGFRb (C) using phosphospecific antibodies in
HPV16 E6 (E6) or LXSN control vector (C) expressing stable HFKs. Representative experiments from three independent experiments are shown in
panels A, B and C. Quantifications relative to actin are shown below each panel.
doi:10.1371/journal.ppat.1003237.g001
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RPTK signaling and downstream effector cascades is correlated
with increased internalization of activated receptors.
The signaling adaptor protein GRB2 is critical for HPV16
E6 mediated EGFR internalization and mTORC1 activation
The signaling adapter protein GRB2 associates with EGFR
phosphorylated at Y1068 and activates PI3K and MAPK
signaling. In addition GRB2 has also been implicated as a critical
mediator of EGFR internalization. GRB2 can interact with
dynamin, a GTPase that is important for inclusion of receptors
into vesicles during endocytosis [30].
To determine if GRB2 may be important for HPV16 E6
mediated EGFR internalization we depleted GRB2 by RNA
interference and evaluated co-localization of EGF with EEA1 after
15 minutes by fluorescence microscopy. Similar to Fig. 4B and C,
HPV16 E6 expressing primary HFKs transfected with siCtrl had
an increased number of EGF positive early endosomes in
comparison to control HFKs (Control siCtrl=5.2960.23;
HPV16 E6 siCtrl=8.3761.61 EGF/EEA1 positive vesicles/cell,
Figure 2. Signaling pathways downstream of RPTKs are activated in HPV16 E6 expressing HFKs. (A) Western blot analysis of MAPK
signaling by analyzing ERK1/2 and RSK phosphorylation in HFKs with stable expression of HPV16 E6 (E6) or LSXN control vector (C) and experiencing
nutrient withdrawal by PBS starvation for 30 minutes. Quantifications relative to actin are shown below each panel. A representative experiment from
a total of four independent experiments is shown. (B) HPV16 E6 mediated increase in cap dependent translation is dependent on MEK and mTORC1
signaling. U2OS cells were transfected with pFR_CrPV_xb and the indicated plasmids and processed for firefly and Renilla luciferase activity at
48 hours post transfection. 20 hours prior to lysis, cells were treated with DMSO, 10 mM U0126 (a MEK inhibitor), or a combination of 10 mM U0126
and 100 nM Rapamycin (an mTORC1 inhibitor). Firefly and Renilla luciferase were normalized to levels in DMSO treated cells and are presented as fold
changes of normalized firefly relative to normalized Renilla activity. The bar graph represents averages and standard deviations of three independent
experiments, each performed in triplicate; the asterisk indicates statistical significance (P,0.05).
doi:10.1371/journal.ppat.1003237.g002
Figure 3. RPTK inhibition reduces mTORC1 activation in HPV16 E6 expressing HFKs. (A) Western blot analysis of EGFR and mTORC1
activation (S6K) in HFKs with stable expression of HPV16 E6 (E6) or pLentiN6.3 control vector (C) following EGFR inhibition with Gefitinib. Cells were
treated with DMSO or 1 mM Gefitinib over a 24 hour time course. Actin blots are shown as loading controls. The experiment shown here represents
one of three independent experiments. (B) Western blot analysis of INSRb/IGFRb and mTORC1 activation (S6K) in HFKs with stable expression of
HPV16 E6 (E6) or pLentiN6.3 control vector (C) following INSRb/IGFRb chemical inhibition with OSI-906. These data represent one of two independent
experiments. Cells were treated with DMSO or 150 nM OSI-906 over a 6 hour time course. Actin blots are shown as a loading control; ‘‘actin 1’’
corresponds to the blots with the phosphospecific antibodies, ‘‘actin 2’’ corresponds the other blots.
doi:10.1371/journal.ppat.1003237.g003
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the increase in the number of EGF/EEA1 positive vesicles in
HPV16 E6 expressing HFKs to levels similar to control cells
(Control siGRB2=5.6560.45; HPV16 E6 siGRB2=5.9660.59
EGF/EEA1 positive vesicles/cell) (Figure 5A and B). Interestingly,
GRB2 depletion in control HFKs had no effect on the number of
EGF positive EEA1 vesicles per cell.
We next utilized GRB2 depletion to determine whether GRB2
function is important for HPV16 E6 mediated mTORC1
activation. GRB2 depletion markedly reduced phosphorylation
of the mTORC1 surrogate marker S6K in HPV16 E6 expressing
HFKs. Interestingly, however, there was no detectable reduction
of S6K phosphorylation when GRB2 was depleted in control
HFKs (Figure 5C).
These results show that GRB2 is required to enhance EGFR
internalization and likely perpetuate signal transduction originat-
ing from internalized receptors in HPV16 E6 expressing cells.
Further, even though HPV16 E6 expression causes increased
EGFR phosphorylation at multiple tyrosine residues and therefore
is predicted to activate multiple downstream signaling pathways,
signaling through GRB2 is critical for HPV16 E6 mediated
mTORC1 activation.
Increased cellular migration through a RPTK dependent
mechanism in HPV16 E6 expressing HFKs
We have shown that HPV16 E6 activates two RPTK effector
signaling pathways: mTORC1 [16] and the MAPK pathway
(Figure 2). Activation of these two pathways promotes cellular
events that are associated with carcinogenesis including cellular
migration (reviewed in [31,32]). Therefore, we tested the
hypothesis that HPV16 E6 mediated RPTK activation may
increase cellular migration by performing wound healing and
transwell migration assays. Wound healing assays were performed
by scratching primary or hTERT immortalized HFK monolayer
cultures grown in EGF deficient media and following wound
closure over time. HFKs with stable HPV16 E6 expression
migrated to close the wounded area in the absence of EGF with
greater efficiency than control vector transduced HFKs (Figure 6A
and B, relative reduction in the wound surface area at t=13 h,
0.260.06 and 0.8760.09, respectively; P,0.0001). We next
determined if RPTK inhibition may inhibit cellular migration in
HPV16 E6 expressing HFKs. Treatment with the EGFR inhibitor
Gefitinib or the INSR/IGFR inhibitor OSI-906 impaired
increased migration of HPV16 E6 expressing cells to a level
similar to that of empty vector expressing cells (Figure 6A and B
Figure 4. Internalization and degradation of activated receptor species are increased in HPV16 E6 expressing HFKs. (A) Western blot
analysis of EGFR and INSRb/IGFRb following receptor internalization. After washing the cells with PBS they were incubated with biotin disulfide N-
hydroxysulfosuccinimide ester for 40 minutes at 4uC followed by inactivation of the biotin reagent with NH4Cl for 10 min at 4uC. Cells were then
stimulated with KSFM lacking growth factors and supplements for 3 hours at 37uC. Following ligand independent stimulation, cells were either lysed
without reduction to measure surface bound receptors (S) or reduced and lysed to measure ligand independent internalization (I), Internalization
assays were performed as described in the Materials and Methods. Levels of EGFR and INSRb/IGFRb in a 5 mg sample, representing 2% of the
internalization assay, together with actin, are shown in the left panel (Input), and the resulting streptavidin affinity purification (AP) is shown in the
right panel. Quantification representing the ratio of phosphorylated receptors to total receptors normalized to control vector (C) internalized
phosphorylated receptors is shown below applicable panels. This experiment represents one of two independent experiments. (B)
Immunofluorescence analysis of EGF co-staining with the endosomal marker EEA1 in HFKs with stable expression of HPV16 E6 (E6) or pLentiN6.3
control vector (C) following overnight starvation and stimulation with Alexa 647 labeled EGF (EGF) for 15 minutes. Cells were stained with Hoechst to
visualize the nuclei. The scaling bar represents 40 mm. (C) Quantification of the number of EGF positive early endosomes from panel B. Bar graphs
represent average numbers of EGF positive early endosomes per cell from four independent experiments. A total of 115 cells were evaluated. Error
bars indicate standard deviations; the asterisk indicates statistical significance (P=0.0017).
doi:10.1371/journal.ppat.1003237.g004
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and 0.9660.07; P=0.86 (Gefitinib), 0.8360.05 and 0.8460.17
(OSI-906); P=0.1103, respectively). As expected, inhibition of
mTORC1 or MEK signaling similarly inhibited increased
migration of HPV16 E6 expressing cells to levels of control HFKs
(Figure 6A and B, relative reduction in surface area at t=13 h,
0.6760.01 and 0.8560.22; P=0.3716 (Rapamycin), 0.8660.1
and 0.8760.04; P=0.9816 (U0126), respectively.) HPV16 E6 also
increased cellular migration in wound healing assays in the
presence of EGF and this was dependent on RPTK activity
(Figure S2). To confirm that the ability of HPV16 E6 to promote
wound closure was independent of cell proliferation, we inhibited
proliferation with Mitomycin C and evaluated wound closure. As
expected, HPV16 E6 expression enhanced cellular migration in
the presence and absence of Mitomycin C (Figure 6C). Moreover,
expression of HPV16 E6 in hTERT immortalized HFKs also
caused increase cellular migration in wound healing assays
(Figure 6D).
To independently validate these results, we also evaluated if
HPV16 E6 increases migration of HFKs through a size restricting
membrane in a transwell migration assay in the absence of EGF.
These experiments could be performed over a much shorter time
course than the wound healing assays, which further alleviates
concerns regarding potential contributions of cell division.
Enhanced migration of HPV16 E6 expressing cells through the
membrane was observed as early as one hour in cells grown in the
absence of EGF (Figure 6E, total number of migrating cells at
t=1 h, Control: 2766.69; E6: 45.5563.66; P=0.04).
Figure 5. The signaling adaptor protein GRB2 is critical for HPV16 E6 mediated EGFR internalization and mTORC1 activation. (A)
Immunofluorescence analysis of EGF co-staining with the endosomal marker EEA1 in GRB2 depleted (siGRB2) or control siRNA transfected (siCtrl)
HFKs with stable expression of HPV16 E6 (E6) or pLentiN6.3 control vector (C) following overnight starvation and subsequent stimulation with Alexa
647 labeled EGF (EGF) for 15 minutes. Cells were stained with Hoechst to visualize the nuclei. The scaling bar represents 20 mm. (B) Quantification of
the number of EGF positive early endosomes from panel A. Bar graphs represent average numbers of EGF positive early endosomes/cell with counts
done in triplicate for a total of at least 95 analyzed cells per condition. Error bars indicate standard deviations; the asterisk indicates statistical
significance (P=0.03). (C) Western blot analysis of S6K T389 in GRB2 depleted (siGRB2) or control siRNA transfected (siCtrl) HFK populations with
stable expression of HPV16 E6 (E6) or control vector (C). Cells were transfected with the corresponding siRNAs at 48 hours prior to lysis. An actin blot
is shown as a loading control and quantifications relative to actin are shown below each panel. A representative experiment taken from four
independent experiments is shown in panel C.
doi:10.1371/journal.ppat.1003237.g005
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PLOS Pathogens | www.plospathogens.org 6 March 2013 | Volume 9 | Issue 3 | e1003237These results suggest that HPV16 E6 expression causes
increased migration of primary HFKs in the absence of EGF,
and that EGFR/INSR/IGFR effector signaling pathways are
required for efficient HPV16 E6 mediated cellular migration.
Discussion
We previously presented evidence that HPV16 E6 causes
mTORC1 activation and increases cap dependent translation
through PDK1 and mTORC2 dependent mechanisms [16].
While the mechanism of HPV16 E6 induced mTORC2 activation
remains unknown, we focused on investigating signal transduction
pathway that results in enhanced PDK1 activity in HPV16 E6
expressing HFKs. PDK1 phosphorylation is a result of increased
RPTK and PI3K signaling, which is regulated by the activity of
protein and lipid phosphatases. We evaluated the total protein
levels of PTEN and several other phosphatases that act in this
pathway and found no change in total protein levels in HPV16 E6
expressing HFKs in comparison to control cells under normal
growth conditions or nutrient deprived conditions (Figure S3A, B).
Since PTEN activity is regulated by subcellular localization
[33,34], we performed immunofluorescence analyses. There was
no evidence for changes in PTEN subcellular localization in
HPV16 E6 expressing HFKs as compared to control HFKs
(Figure S3C). HPV16 E6 was previously shown to associate with
the PTPN3/PTPH1 and PTPN13 tyrosine phosphatases and
target them for proteasome mediated degradation [5,10]. We did
not detect an association of HPV16 E6 with PTPN3 or PTPN13,
and therefore did not address whether and/or how these
associations may contribute to HPV16 E6 mediated RPTK
activation.
Here we present evidence that the PDK1 dependent component
of mTORC1 stimulation is activated through RPTKs including
ERBB2, EGFR, INSR and IGFR (Figure 1). Interestingly HPV16
E6 expression causes RPTK hyperactivation in the presence of
growth factors and causes prolonged activity when ligands are
withdrawn. Activation of downstream signaling cascades including
the MAPK pathway was also demonstrated. EGFR or INSR/
IGFR inhibition abrogated HPV16 E6 mediated mTORC1
activation as indicated by reduced phosphorylation of the
Figure 6. HPV16 E6 increases cellular migration in EGF depleted cells. (A) Wound healing assays with primary HFKs stably expressing HPV16
E6 (E6) or infected with pLentiN6.3 control vector (C) following wounding of the cellular monolayer in the absence of EGF following RPTK and effector
pathway inhibition. Cells were treated with DMSO or 100 nM Rapamycin, 1 mM Gefitinib, 150 nM OSI-906, or 10 mM U0126 and closure of the
monolayer was measured over a 25 hour time course. Only images of the DMSO treated samples are shown (B). Quantification of wound closure as
shown in (A). Surface areas of wounds were calculated relative to the surface area of the wounds at t=0 hour. Bar represent averages and standard
deviations of three experiments; asterisks indicate statistical significance (P,0.0001). (C) Quantification of wound closure in the presence of 8 mg/ml
Mitomycin C to inhibit cellular proliferation. (D) Quantification of wound closure in immortalized HFKs stably expressing HPV16 E6 (E6) or pLentiN6.3
control vector (C) (E). Transwell migration assay with HFKs stably expressing HPV16 E6 (E6) or pLentiN6.3 control vector (C). Cells were seeded in the
absence of EGF on the top chamber of a transwell insert and migration to the bottom chamber in the absence of EGF was determined at 30 minutes
and 60 minutes after seeding. The bars represent averages and standard deviations of three experiments; the asterisk indicates statistical significance
(P,0.05).
doi:10.1371/journal.ppat.1003237.g006
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decrease in cap dependent translation and combined inhibition of
MEK and mTORC1 further reduces cap dependent translation.
Hence HPV16 E6 activates cap dependent translation through
two at least partially independent signaling pathways, mTORC1
and MAPK, that are both downstream of RPTKs. These results
support numerous previous studies that have reported activation of
signaling cascades downstream of RPTKs in HPV16 E6
expressing cells [5,35–38]. For example, HPV16 E6 has been
reported to activate FAK signaling, causing disruption of the
cellular cytoskeletal structure [26,27].
Even though HPV16 E6 and E7 have each been reported to
transcriptionally activate EGFR expression [39,40], our experi-
ments did not provide evidence for increased EGFR or INSR/
IGFR protein levels in HPV16 E6 expressing HFKs.
EGFR activation has also been studied in the benign respiratory
papillomas that are caused by low-risk mucosal HPV6b and
HPV11 infections and HPV6b and HPV11 E6 proteins have been
linked to increased EGFR expression [41]. EGFR expression was
not due to a gene amplification event, nor was it associated with an
increase in mRNA expression. Instead, low-risk mucosal HPV E6
proteins have been reported to increase EGFR recycling to the cell
surface by approximately 20%. The low-risk HPV E6 associated
increase in EGFR expression was accompanied by enhanced
EGFR tyrosine phosphorylation and increased MAPK activity
[41]. In contrast to these studies, we did not detect an increase in
total receptor levels in HPV16 E6 expressing HFKs, but rather a
specific increase in phosphorylated, active receptor species.
We demonstrate that HPV16 E6 increases internalization of
phosphorylated, active EGFR, INSRb and IGFRb in the absence
of growth factors (Figure 4). Consistent with these studies we also
report that HPV16 E6 expression enhances EGF localization,
presumably bound to EGFR, to early endosomes, suggesting that
HPV16 E6 activates RPTK signaling in the presence or absence of
growth factors. RPTK activation causes increased receptor
internalization, and internalized receptors maintain signaling
potential since they are phosphorylated at residues that promote
receptor association with signaling adaptor proteins and cause
activation of downstream signaling cascades [24]. Moreover,
EGFR receptor internalization is required for the maintenance of
AKT activation [24,42].
Our results show that GRB2 is an important mediator of the
HPV16 E6-mediated increase in receptor internalization as GRB2
depletion reduces EGF internalization specifically in HPV E6
expressing cells (Figure 5). The molecular mechanisms accounting
for this observation remain to be determined.
The mechanics of GRB2-receptor association and activation is
different for different RPTKs. GRB2 associates directly with
phosphotyrosine 1068 of activated EGFR [43]. In contrast, INSR
and IGFR form indirect interactions with GRB2 via the IRS-1
and SHC adaptor proteins [44]. The PDGFR/GRB2 interaction
is indirect, with SHP-2 mediating the association [45]. Similarly,
the EPHA2-GRB2 association is also indirect, requiring SHC to
form a complex that then leads to the activation of downstream
signaling cascades including MAPK activation [46]. Given that
GRB2 is an important effector of multiple RPTKs and that only a
subset of these receptors are activated in HPV16 E6 expressing
HFKs (Figure 1), E6 may only function through GRB2 bound to
specific adaptors that are required for receptor internalization.
Taken together, these results form the basis for a model of how
high-risk HPV E6 oncoproteins may contribute to enhanced
receptor activation (Figure 7). We demonstrate that HPV16 E6
expression causes receptor hyperactivation under conditions of
abundant growth factor availability, and that HPV16 E6 causes
prolonged receptor activation under conditions of growth factor or
nutrient deprivation. We postulate that the HPV16 E6-mediated
RPTK phosphorylation recruits GRB2 to the cell membrane
where it functions as a signaling adaptor for PI3K and MAPK
effector pathways and participates in receptor internalization.
According to this model, prolonged activation of the PI3K and
MAPK effector signaling pathways enhances cap dependent
translation and cellular migration.
E5 is the major transforming protein of the bovine papilloma-
virus type 1 (BPV1). This small, single pass transmembrane
protein transforms cells by forcing dimer formation and thus
activation of RPTKs including EGFR and PDGFR in the absence
of any growth factor ligands [47]. It is tempting to speculate that
HPV16 E6 and BPV1 E5 may have both evolved to short-circuit
RPTK signaling for similar requirements of the viral life cycle,
presumably to keep RPTK signaling active in virally infected cells
so as to avoid elimination by cell intrinsic tumor suppressor
mechanisms such as the trophic sentinel pathway [18]. However,
BPV1 E5 is a much more potent oncogene as growth factor
independent receptor dimerization will sustain RPTK activation
indefinitely in the absence of growth factor since it forces
dimerization and thus persistent activation of these receptors,
whereas HPV16 E6 will only sustain signaling for a relatively short
period of time after growth factor withdrawal.
The HPV E6 and HPV E7 proteins share biological activities
with proteins encoded by other DNA tumor viruses, including
polyomaviruses SV40, Merkel cell polyomavirus (MCPyV),
murine polyomavirus, and adenoviruses. The PI3K/AKT/
mTORC1 signaling axis is targeted for activation by many
DNA tumor viruses. The ability of plasma membrane bound
mouse polyomavirus Middle T antigen to activate AKT and other
downstream mitogenic pathways through association and subse-
quent recruitment of the Class I PI3K p85 regulatory subunit has
been well documented [48–51]. It was recently reported that the
MCPyV small T antigen causes aberrant hyperphosphorylation
and activation of eukaryotic translation initiation factor 4E
binding protein (4E-BP1). This study claimed that 4E-BP1
activation is independent of mTORC1 or mTORC2, but no
mechanism was proposed [52]. Hence, small DNA tumor viruses
commonly activate PI3K/AKT/mTORC1 through multiple,
diverse mechanisms. These mechanisms are not mutually exclu-
sive and may account for activation of a variety of signaling
pathways including MAPK, mTORC1 and FAK signaling.
Last but not least, these results also suggest that small molecule
inhibitors of RPTKs and/or downstream effector pathways will
deprive HPV16 infected cells of a crucial survival cue and may
have therapeutic efficacy in HPV associated lesions and cancers.
Materials and Methods
Plasmids
Plasmids used in this study include the retroviral vectors pLXSN
(control) and pLXSN HPV16 E6 [53]; and pCMV N (control) and
pCMV HPV16 NE6no* [54–56]. Lentiviral vectors including
pLentiN (control) and pLenti HPV16 NE6no* were generated by
Gateway cloning into the pLenti6.3 Gateway compatible vector
(Invitrogen). For the purposes of this study, the HPV16 E6
expression vectors were mutagenized such that they no longer
have the capacity to generate the major splice variants [56,57].
Mutagenesis yields a coding mutation in E6 (HPV16 E6 V42L)
that does not interfere with the ability of HPV16 E6 to contribute
to epithelial cell immortalization [57]. The pFR_CrPV_xb
bicistronic firefly/Renilla luciferase vector [28] was obtained from
Phil Sharp through Addgene (plasmid 11509) and was used to
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[16,56].
Cell lines and culture
293T and U2OS cells (ATCC) were maintained in Dulbecco’s
modified Eagle medium (DMEM) (Invitrogen), supplemented with
10% fetal bovine serum (FBS), 50 U/ml penicillin and 50 mg/ml
streptomycin. Primary human foreskin keratinocytes were isolated
from anonymous newborn circumcisions as previously described
[58], and maintained in keratinocyte serum-free medium (KSFM)
supplemented with human recombinant epidermal growth factor
1–53, bovine pituitary extract (Invitrogen), 50 U/ml penicillin and
50 mg/ml streptomycin, 20 mg/ml gentamicin, and 1 mg/ml
amphotericin B. Human hTERT immortalized cl398 keratino-
cytes (iHFKs) were obtained from Dr. A. Klingelhutz (U. Iowa).
HPV oncogene expressing primary and immortalized HFKs were
generated by retroviral infection with the corresponding pLXSN
based vectors or by lentiviral infection with the corresponding
pLenti6.3N based vectors following selection with 250 mg/ml
G418 or 3 mg/ml blasticidin, respectively. All experiments
performed with primary HFK populations were done so with
donor and passage matched HFK populations passaged less than
ten times. For nutrient deprivation assays, HFKs were grown to
90% confluence, at which point they were washed twice with
phosphate buffered saline (PBS), followed by incubation in either
PBS for 15 minutes or KSFM lacking EGF for 2 hours prior to
analysis. HFKs were grown on poly-D-lysine coated plates (BD
Biosciences) for PBS starvation experiments.
Western blotting and antibodies
Unless otherwise indicated, protein lysates were prepared by
incubating the cells in ML buffer (300 mM NaCl, 0.5% Nonidet
P-40 [NP-40], 20 mM Tris-HCl [pH 8.0], 1 mM EDTA)
supplemented with one complete EDTA-free protease inhibitor
cocktail tablet (Roche) per 25 ml lysis buffer and one PhosSTOP
phosphatase inhibitor cocktail tablet (Roche) per 7.5 ml lysis buffer
on ice for 20 minutes. Cell lysates intended for global phosphotyr-
osine Western blots were prepared by incubating the cells in RIPA
buffer (150 mM NaCl, 1% NP-40, 0.5% Deoxycholic acid
[DOC], 0.1% SDS, 50 mM Tris-HCl [pH 7.5]), supplemented
as described above for ML Buffer with the addition of 50 mM
Pervanadate) on ice for 20 minutes. Cells were then scraped and
lysates cleared by centrifugation at 16,1106g for 10 min at 4uC.
Protein concentrations were determined using the Bradford
method (Bio-Rad). Proteins were separated by SDS-PAGE and
electrotransferred onto polyvinylidene difluoride membranes
(Immobilon-P; Millipore). Unless otherwise noted, membranes
were blocked in 5% nonfat dry milk in TBST (137 mM NaCl,
2.7 mM KCl, 25 mM Tris [pH 7.4], 0.1% Tween 20) and probed
with the appropriate antibody. The following antibodies were used
at a 1:1000 dilution unless otherwise specified: b-Actin (1501;
Chemicon), p53 (Ab-6, Calbiochem), GRB2 (ab86713, Abcam),
Flag (4 mg/ml, F3165, Sigma), anti-phosphotyrosine (05-1050X,
Millipore), EGFR (4267), EGFR Y992 (2235), EGFR Y1068
(3777), EGFR Y1173 (4407), S6K (9202), S6K T389 (9206), RSK
(9333), RSK S380 (9335), ERK1/2 (9102), ERK1/2 T202/Y204
(4370), IGF-1Rb (3027), IGF-1Rb Y1135/36/INSRb Y1150/51
(3024), PI3K p110a (4249), PI3K p110b (3011), PI3K Class III
(3358), PTEN (9188), all from Cell Signaling Technology.
Secondary anti-mouse and anti-rabbit antibodies conjugated to
horseradish peroxidase were used at dilutions of 1:10,000 or
1:15,000, respectively. Proteins were visualized by enhanced
chemiluminescence (Perkin Elmer, Millipore) and exposed on
Kodak BioMax XAR film, or electronically acquired and
quantified with a Kodak Image Station 4000R equipped with
Kodak Imaging Software, version 4.0, or with a Carestream Gel
Logic 4000 pro, equipped with Kodak Imaging Software, version
4.0.
Receptor internalization assay
Primary HFKs were seeded into 15 cm dishes and internaliza-
tion and degradation assays were performed when the cells
Figure 7. Hypothetical model. HPV16 E6 expressing cells (right) show enhanced activation of RPTKs at least in part by enhancing internalization of
activated receptor species as compared to parental cell (left). As a consequence, downstream signaling circuits, including mTORC1 activity remain
active even under conditions of limited growth factor availability. See text for details.
doi:10.1371/journal.ppat.1003237.g007
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CM (PBS, 0.1 mM CaCl2, 1 mM MgCl2) followed by incubation
in 5 ml of 0.5 mg/ml biotin disulfide N-hydroxysulfosuccinimide
ester (sulfo NHS-SS-Biotin, Pierce) in PBS-CM by rocking at 4uC
for 40 minutes. Cells were then washed two additional times in
PBS-CM and incubated with PBS containing 50 mM NH4Cl for
10 min, rocking at 4uC, followed by two washes in PBS-CM.
KSFM without any growth factors and supplements was added to
one plate in order to investigate ligand independent receptor
internalization over 180 minutes at 37uC. Following the 180 min-
ute stimulation with KSFM lacking growth factors and supple-
ments, cells were washed twice with PBS-CM and reduced by
washing twice for 15 min each with Glutathione Buffer (50 mM
reduced glutathione, 90 mM NaCl, 1 mM MgCl2, 0.1 mM
CaCl2, 60 mM NaOH) rocking at 4uC. Cells were then washed
twice with PBS-CM followed by one 15 min wash with PBS
containing 50 mM Iodoacetamide (PBS-IAA), rocking at 4uC.
Total cell surface receptors were measured by directly lysing one
plate without stimulation or subsequent glutathione reduction.
Lysates were then prepared by incubating cells with ID lysis buffer
(200 mM NaCl, 75 mM Tris [pH 7.5], 2.5 mM EDTA, 2.5 mM
EGTA, 1.5% Triton X-100, 0.75% NP40, 0.1% SDS), supple-
mented with one complete EDTA protease inhibitor cocktail
tablet (Roche) and one PhosStop phosphatase inhibitor cocktail
tablet (Roche). Receptor internalization assays were performed by
pre-clearing lysate with 40 ml Pansorbin (Calbiochem) for 45 min,
after which the Pansorbin was removed by centrifugation at
16,1106g for 10 min at 4uC. The pre-cleared lysate was then
incubated with 40 ml of washed Streptavidin-agarose resin
(Thermo Scientific) for 16 hours, rocking at 4uC, after which the
beads were washed four times in ID buffer, 26sample buffer was
added, and proteins separated by SDS PAGE and electrotrans-
ferred onto PVDF for Western blotting.
Immunofluorescence microscopy
For immunofluorescence analysis, cells were seeded onto glass
coverslips 48 hours prior to fixation. Cells were washed two times
with PBS and incubated with KSFM without any growth factors
or supplements at 37uC for 16 hours. Cells were then stimulated
with KSFM containing 150 mg/ml Alexa Fluor 647 EGF
(Molecular Probes), fixed with 4% paraformaldehyde in PBS,
washed with PBS, and permeabilized with 0.1% Triton-X100/
1 mM Glycine in PBS for 10 min at room temperature. Following
permeabilization, cells were washed with PBS and blocked first for
one hour with 5% goat serum at 4uC and then with 2% BSA for
10 min at room temperature. Cells were incubated with anti-
EEA1 (610457, BD) for one hour at room temperature. The
secondary antibody was goat anti-mouse Alexa Fluor 488
(Molecular Probes) and was used at a 1:1000 dilution. Nuclei
were stained with Hoechst 33258. Images were acquired using a
Nikon 80i upright microscope equipped with a Hamamatsu
C8484-03 camera and processed using MetaMorph 7 software.
Wound healing assay
Primary or immortalized HFKs were seeded into 6 cm dishes
and a wound was introduced into the monolayer with a p200
pipette tip when the cells reached 90% confluence. Just prior to
wounding the monolayer, the cells were washed two times with
PBS and the media was replaced with KSFM lacking EGF for the
minus EGF condition or with complete KSFM for the plus EGF
condition, plus inhibitors when applicable. Cell proliferation was
inhibited with the addition of 8 mg/ml Mitomycin C, where
indicated. The cells were then incubated at 37uC and images of
the wounded monolayer were captured over a time course using a
Zeiss Axiovert 200 light microscope equipped with the Axiovision
Release 4.4 SP2 software package. The wound surface area of
each resulting image was calculated using Image J software (NIH).
The surface area of the wound relative to the samples at t=0 was
determined. A total of at least 3 independent experiments were
performed and statistical significance was calculated using the
Student’s T test.
Transwell migration assay
Primary HFKs were trypsinized and resuspended in KSFM
minus EGF. 30,000 HFKs were resuspended in 150 ml of KSFM
minus EGF and placed in the upper chamber of a transwell
permeable support membrane insert (8.0 mM, Costar product
3422) pre-wetted with 50 ml KSFM minus EGF. The bottom
chamber was filled with 600 ml KSFM minus EGF, and the cells
were incubated at 37uC for 30 minutes or one hour. Cells were
then scraped from the upper chamber of the transwell membrane
and the membrane was fixed with 100% methanol for 30 minutes
and stained with Crystal Violet. Cells remaining on the underside
of the membrane were then counted in three separate fields of
view per experiment. A total of three independent experiments
were performed and statistical significance calculated using the
Student’s T test.
Transfections and luciferase assays
U2OS cellsweretransfectedandprocessedforluciferase assaysas
described previously [16]. The fold change in activity was
determined by calculating the ratio of firefly luciferase activity to
Renilla luciferase activity compared to the control vector-transfect-
ed cells. Three independent experiments were performed and the
Student’s T test was used to calculate statistical significance.
siRNA transfections
HFKs were seeded in 6 well dishes in triplicate and GRB2
siRNA (smart pool L-019220-00, Dharmacon) or scrambled
siRNA was transfected with Lipofectamine 2000 (Invitrogen) to
a final concentration of 40 nM. Lysates were prepared 72 hours
post transfection.
Supporting Information
Figure S1 MEK inhibition reduces HPV16 E6 mediated
activation of MAPK signaling. Western blot analysis of
MAPK signaling (ERK1/2 and RSK) in primary HFKs with
stable expression of HPV16 E6 (E6) or LXSN control vector (C).
Cells were treated with DMSO or 15 mM U0126 at 30 minutes
prior to lysis.
(TIF)
Figure S2 HPV16 E6 increases cellular migration in the
presence of EGF. (A). Wound healing assay with HFKs stably
expressing HPV16 E6 or pLentiN6.3 control vector following
wounding of the cellular monolayer grown in ‘‘rich’’, standard
KSFM following RPTK and effector pathway inhibition. Cells
were treated with DMSO or 100 nM Rapamycin, 1 mM Gefitinib,
150 nM OSI-906, or 10 mM U0126 and closure of the monolayer
was measured over a 25 hour time course. (B). Quantification of
wound closure as shown in panel A. Surface area of wounds were
calculated relative to the surface area of the wounds at t=0 hour.
The bars represent averages and standard deviations of four
experiments for DMSO treated samples and two experiments for
drug treated samples; asterisks indicate statistical significance
(P,0.05).
(TIF)
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is not due to the destabilization or change in localization
of PTEN and other phosphatases. (A) Western blot analysis
of the dual specificity phosphatase PTEN in HFKs with stable
expression of HPV16 E6 (E6) or control vector (C) of under
normal growth conditions (KSFM). (B) Western blot analysis of
PTEN, SHP1/PTPN6 and PTP1b/PTPN1 in HFKs with stable
expression of HPV16 E6 (E6) or control vector (C) under
conditions of nutrient deprivation (PBS, 15 minutes). (C) Confocal
immunofluorescence imaging of PTEN (green) subcellular local-
ization in control or HPV16 E6 expressing HFKs. Nuclei are
stained with DRAQ5 (blue).
(TIF)
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